Greenphire, ERT Tie Patient Reporting and Compensation
Greenphire announced a strategic partnership with ERT
Greenphire, a provider of payment technology for the clinical trial industry, announced a strategic partnership with ERT, a provider of high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire's ClinCard System with ERT's electronic patient reported outcomes (ePRO) technology. The goal is to link patient reporting to compensation to enhance patient engagement and compliance.
This partnership will enable sponsors and CROs to offer real-time compensation to patients for compliance with study protocols by linking their ePRO activity to a ClinCard personal debit card. In addition to using Greenphire's system to compensate participants with stipends for site visits, clients can customize out-of-office reimbursement for patients' time and effort based on the specific requirements of each protocol.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
